Jim Simons’s LAVA Therapeutics LVTX Stock Holding History

Jim Simons’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,600	Closed	-$18K	–	4118
2023 Q1	$18K	Sell	10,600 -8,200	-44%	-$23K	﹤0.01%	3839
2022 Q4	$66K	Buy	+18,800	New	+$86.3K	﹤0.01%	3737

Other funds holding LVTX

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jim Simons's LVTX Position: Q2 2023 in Review

Jim Simons sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 10,600 shares — an estimated $18K sold.

Jim Simons first reported a position in LVTX in Q4 2022 and held it in 2 quarters. The position peaked at $66K in Q4 2022. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

Jim Simons reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
Jim Simons sold 10,600 LAVA Therapeutics shares in Q2 2023, an estimated $18K.
Jim Simons first reported a position in LAVA Therapeutics in Q4 2022 and held it in 2 quarters.
Jim Simons's LAVA Therapeutics position peaked at $66K in Q4 2022.
15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.